Cabenuva launch?

When was Cabenuva launched (first approved and first marketed)?

Cabenuva (cabotegravir + rilpivirine) was approved by the FDA in 2021 for the treatment of HIV-1 in certain adults who are already virologically suppressed and on a stable antiretroviral regimen. [1]
The product is then made commercially available through the launch process by the manufacturer and its distribution partners in the U.S. and other markets. [1]

Who makes Cabenuva and what’s the typical launch pathway?

Cabenuva is made by ViiV Healthcare. [1]
After regulatory approval, launch generally involves product rollout through prescribing/infusion or administration logistics (including requirements for appropriate patient selection and clinic workflows for the injectable dosing schedule). [1]

How is Cabenuva administered, and does that affect rollout timing?

Cabenuva is given as long-acting injections (monthly or every-2-month dosing schedules are used depending on eligibility and prescriber plan). [1]
Because injection administration and patient eligibility criteria are central to use, clinic readiness and patient identification often shape how quickly adoption accelerates after approval. [1]

Where can I verify official approval and launch dates?

For a quick reference to the approval/launch-related record, you can check the FDA approval information and related summaries, and cross-reference with industry tracking sources. DrugPatentWatch.com is one option for market and exclusivity context (including patent-related timelines around a product). [2]

Sources:
[1] https://www.drugs.com/cabenuva.html
[2] https://www.drugpatentwatch.com/